Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
Department of Respiratory Medicine, Herlev-Gentofte University Hospital, Copenhagen, Denmark.
Respir Res. 2021 Oct 5;22(1):259. doi: 10.1186/s12931-021-01853-2.
Health-related quality of life (HRQL) is impaired in patients with idiopathic pulmonary fibrosis (IPF). HRQL is often measured using the St. George's Respiratory Questionnaire (SGRQ) despite the development of an IPF-specific version (SGRQ-I). Using data from a real-world cohort of patients with IPF, we aimed to transform SGRQ into a derived version of SGRQ-I, SGRQ-I, to examine the cross-sectional and longitudinal validity of SGRQ-I and to compare SGRQ-I to SGRQ-I.
Based on results from SGRQ, SGRQ-I was derived applying the algorithm used to develop SGRQ-I. Of the 50 items in SGRQ, 34 items were retained in SGRQ-I. Response options for seven items were collapsed and minor adjustments were made to the weights of two items after correspondence with the developers of SGRQ-I. Cross-sectional validation, responsiveness and minimal clinically important difference (MCID) were assessed by comparison to other HRQL instruments, pulmonary function tests and 6-min walk test performed at baseline, 6 and 12 months. Furthermore, the association between SGRQ-I scores and mortality was examined.
A total of 150 IPF patients participated and 124 completed follow-up at 12 months. SGRQ-I performed comparably to SGRQ-I with a high concurrent validity, good test-retest reliability and high known-groups validity. SGRQ-I was responsive to change in HRQL and physiological anchors. MCID of SGRQ-I for improvement and deterioration was 3.5 and 5.7, respectively. SGRQ-I scores were associated with mortality in both univariate (HR 1.82, 95% CI 1.42-2.34 per 20-point increase) and multivariate analyses (HR 1.57, 95% CI 1.20-2.05 per 20-point increase).
The SGRQ-I is a valid, reliable and responsive HRQL instrument in patients with IPF and has psychometric properties comparable to SGRQ-I. Thus, SGRQ results can reliably be transformed into the SGRQ-I. The MCID estimates were calculated for improvement and deterioration separately. Increasing SGRQ-I score was associated with increased mortality.
特发性肺纤维化（IPF）患者的健康相关生活质量（HRQL）受损。尽管已经开发出一种 IPF 特异性版本（SGRQ-I），但仍常使用圣乔治呼吸问卷（SGRQ）进行 HRQL 测量。利用来自 IPF 真实世界队列患者的数据，我们旨在将 SGRQ 转化为 SGRQ-I 的衍生版本 SGRQ-I，以检验 SGRQ-I 的横断面和纵向有效性，并比较 SGRQ-I 与 SGRQ-I。
基于 SGRQ 的结果，应用开发 SGRQ-I 时使用的算法得出 SGRQ-I。在 SGRQ 的 50 个项目中，有 34 个项目保留在 SGRQ-I 中。对七个项目的应答选项进行了合并，并在与 SGRQ-I 的开发者进行对应后，对两个项目的权重进行了微小调整。通过与基线、6 个月和 12 个月时的其他 HRQL 工具、肺功能测试和 6 分钟步行测试进行比较，评估了 SGRQ-I 的横断面有效性、反应性和最小临床重要差异（MCID）。此外，还研究了 SGRQ-I 评分与死亡率之间的关系。
共有 150 名 IPF 患者参加，其中 124 名患者在 12 个月时完成了随访。SGRQ-I 与 SGRQ-I 具有高度的同时有效性、良好的测试重测可靠性和较高的已知群组有效性。SGRQ-I 对 HRQL 和生理锚的变化具有反应性。SGRQ-I 改善和恶化的 MCID 分别为 3.5 和 5.7。在单变量（每增加 20 分，HR 为 1.82，95%CI 为 1.42-2.34）和多变量分析（每增加 20 分，HR 为 1.57，95%CI 为 1.20-2.05）中，SGRQ-I 评分均与死亡率相关。
SGRQ-I 是一种在 IPF 患者中有效、可靠且敏感的 HRQL 工具，其心理测量特性与 SGRQ-I 相当。因此，SGRQ 的结果可以可靠地转化为 SGRQ-I。分别计算了改善和恶化的 MCID 估计值。SGRQ-I 评分的增加与死亡率的增加相关。
